ArticleScience advances2021
Nanotransfection-based vasculogenic cell reprogramming drives functional recovery in a mouse model of ischemic stroke.
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 51 citations in OpenAlex.
- Direct neuronal reprogramming: emerging therapeutic strategies for neurodegenerative disorders.Annals of medicine · 2026Review
- In Vivo Direct Reprogramming: Current Progress and Future Prospects from Mechanisms to Therapeutic Application.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Vasculogenic tissue nanotransfection accelerates functional recovery after peripheral nerve injury.Science advances · 2026Article
- GPR35 protects against reperfusion injury in ischemic stroke by binding with the CR2 domain of Raf1.Journal of neuroinflammation · 2026Article
- Cell phenotypic conversion and fate change during the host defense response, tissue injury and repair.Pharmacology & therapeutics · 2026Review
- Direct in vivo reprogramming to relieve tissue ischemia via induced vasculogenesis.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Cell and tissue reprogramming: Unlocking a new era in medical drug discovery.Pharmacological reviews · 2025Review
- Association of Serum Cystatin C with Stroke Morbidity and All-Cause and Cardio-Cerebrovascular Mortality: Evidence from the NHANES.Healthcare (Basel, Switzerland) · 2025Article
- Prognostic value of lipid variability for recurrence and mortality in elderly patients with acute ischemic cerebrovascular disease.American journal of translational research · 2025Article
- Tissue nanotransfection and cellular reprogramming in regenerative medicine and antimicrobial dynamics.Frontiers in bioengineering and biotechnology · 2025Review
- Repeated Mesenchymal Stem Cell Delivery Attenuates UHMWPE Wear Particle-Induced Osteolysis by Paracrine-Mediated Macrophage Reprogramming.Journal of inflammation research · 2025Article
- Tissue nano-transfection of antimicrobial genes drives bacterial biofilm killing in wounds and is potentially mediated by extracellular vesicles.Journal of controlled release : official journal of the Controlled Release Society · 2024Article
- Vasculogenic skin reprogramming requires TET-mediated gene demethylation in fibroblasts for rescuing impaired perfusion in diabetes.Nature communications · 2024Article
- Quantification of Lymphangiogenesis in the Murine Lymphedema Tail Model Using Intravital Microscopy.Lymphatic research and biology · 2024Article
- Alcohol extract ofBiomedical reports · 2024Article
- Tissue Nanotransfection Silicon Chip and Related Electroporation-Based Technologies for In Vivo Tissue Reprogramming.Nanomaterials (Basel, Switzerland) · 2024Review
- Locomotor activity as an effective measure of the severity of inflammatory arthritis in a mouse model.PloS one · 2024Article
- ICAM-1-decorated extracellular vesicles loaded with miR-146a andBiomaterials science · 2023Article
- Engineered extracellular vesicles from human skin cells induce pro-β-cell conversions in pancreatic ductal cells.Advanced nanobiomed research · 2023Article
- Engineered Extracellular Vesicle-Based Therapies for Valvular Heart Disease.Cellular and molecular bioengineering · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 4 institutions in 2 countries.
Luke R LemmermanDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0001-5564-5410
Maria H H BalchDepartment of Neurosurgery, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0003-2011-6345
Jordan T MooreDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0002-6391-8471
Diego Alzate-CorreaDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0001-5750-0207
Maria A Rincon-BenavidesDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0001-6034-791X
Ana Salazar-PuertaDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, USA.
Surya GnyawaliDepartment of Neurosurgery, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0001-8980-4889
Hallie N HarrisDepartment of Neurosurgery, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0003-4819-0432
William LawrenceDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0001-8639-3420
Lilibeth Ortega-PinedaDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0001-9066-6719
Lauren WilchCoulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA.
Ian B RisserDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0001-8170-3514
Aidan J MaxwellDepartment of Biology, The Ohio State University, Columbus, OH 43210, USA.
Silvia Duarte-SanmiguelDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0002-1171-8945
Daniel DoddDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0003-4095-053X
Gina P Guio-VegaDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0003-2156-6209
Dana M McTigueDepartment of Neuroscience, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0001-7066-9701
W David ArnoldDepartment of Neurology, The Ohio State University, Columbus, OH 43210, USA.
Shahid M NimjeeDepartment of Neurosurgery, The Ohio State University, Columbus, OH 43210, USA.
Chandan K SenDepartment of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA.ORCID 0000-0003-3151-5202
Savita KhannaDepartment of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Cameron RinkDepartment of Neurosurgery, The Ohio State University, Columbus, OH 43210, USA.
Natalia Higuita-CastroDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, USA. gallegoperez.1@osu.edu higuitacastro.1@osu.edu.ORCID 0000-0002-3297-6281
Daniel Gallego-PerezDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, USA. gallegoperez.1@osu.edu higuitacastro.1@osu.edu.ORCID 0000-0002-6263-3191
The Ohio State University · USIndiana University School of MedicineGeorgia Institute of Technology · USUniversidad Nacional de Colombia · CO
Funding
Ohio State Neuroscience Centr CoreP30NS045758 · NINDS · OHIO STATE UNIVERSITY · PI MCTIGUE, DANA M · 2004 to 2015
$7.7MVitamin E Neuroprotection: Novel Molecular MechanismsR01NS042617 · NINDS · OHIO STATE UNIVERSITY · PI SEN, CHANDAN K · 2002 to 2021
$3.9MNovel nanoscale approaches to whole tissue reprogrammingDP2EB028110 · NIBIB · OHIO STATE UNIVERSITY · PI GALLEGO-PEREZ, DANIEL · 2018 to 2022
$2.7MOhio State University Neuroscience Center Core-Core EP30NS104177 · NINDS · OHIO STATE UNIVERSITY · PI BROWN, ANTHONY · 2017 to 2020
$1.9MiGOT neuroprotectionR01NS085272 · NINDS · OHIO STATE UNIVERSITY · PI KHANNA, SAVITA, RINK, CAMERON LUCIAN · 2013 to 2017
$1.7MNon-Viral Modulation of Cutaneous Tissue Plasticity as a Therapy for DiabetesDP1DK126199 · NIDDK · OHIO STATE UNIVERSITY · PI GALLEGO-PEREZ, DANIEL · 2020 to 2020
$737kNanotechnology-based non-viral derivation of induced endothelium for ischemic disordersR21NS099869 · NINDS · OHIO STATE UNIVERSITY · PI GALLEGO-PEREZ, DANIEL, KHANNA, SAVITA · 2016 to 2017
$424kNIBIB NIH HHS DP2 EB028110NIDDK NIH HHS DP1 DK126199NINDS NIH HHS P30 NS045758NINDS NIH HHS P30 NS104177NINDS NIH HHS R01 NS042617NINDS NIH HHS R01 NS085272NINDS NIH HHS R21 NS099869
Abstract
Ischemic stroke causes vascular and neuronal tissue deficiencies that could lead to substantial functional impairment and/or death. Although progenitor-based vasculogenic cell therapies have shown promise as a potential rescue strategy following ischemic stroke, current approaches face major hurdles. Here, we used fibroblasts nanotransfected with
Indexed as
Cellular ReprogrammingIschemic StrokeAnimalsCell DifferentiationDisease Models, AnimalFibroblastsMice
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.